Many insurance plans are dropping coverage for GLP-1 drugs like Zepbound and Wegovy for weight loss, leaving patients like Deborah Finley struggling to afford them. Experts suggest navigating coverage by checking fine print, filing appeals with doctor support, documenting care, seeking discounts, and being cautious with compounded versions.
UPS is investing $48 million in 27 temperature-controlled facilities globally to meet the rising demand for GLP-1 weight-loss drugs and other sensitive medications, ensuring they remain within required temperature ranges for patient use.
A new study suggests GLP-1 drugs, known for weight loss and diabetes treatment, may slow the progression of certain obesity-related cancers. Comparing GLP-1 users to those on DPP-4 inhibitors, researchers found reduced cancer spread in lung, breast, colorectal, and liver cancers.
Four new studies suggest GLP-1 drugs like Wegovy and Mounjaro may improve cancer treatment outcomes. Research indicates lower rates of cancer metastasis and improved survival rates in patients taking these medications.
Millions of people with Medicare will soon be eligible to get discounted GLP-1 drugs for weight loss. Here's how it will work.
The rising popularity of GLP-1 weight-loss drugs is driving a surge in demand for hair-care products as users report temporary hair loss. Beauty companies are now innovating and marketing specific treatments to address this growing side effect.
The increasing adoption of GLP-1 weight loss drugs is creating a significant opportunity for the U.S. apparel industry, with analysts predicting a substantial boost in clothing sales and spending as consumers refresh their wardrobes after significant weight loss.
